

Attorney's Docket No. 02/281858

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Moretti *et al.* Attn: DO/US
International Appl. No.: PCT/EP03/03453
International Filing Date: April 2, 2003
For: INHIBITORS OF CASPASE-3-MEDIATED CLEAVAGE OF
ESSENTIAL VENTRICULAR MYOSIN LIGHT CHAIN AND
TREATMENT OF HEART FAILURE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The patents listed on the attached PTO-1449 were cited in the International Search Report of corresponding International Application No. PCT/EP03/03453. A copy of the Search Report is enclosed for the Examiner's convenience. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.


Respectfully submitted,



David M. Saravitz

Registration No. 55,593

ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260
Customer No. 00826

"Express Mail" Mailing Label Number EV 390050085 US
Date of Deposit: September 24, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, Alexandria, VA 22313-1450.

Karyn Grimm

10/508848

10/508848 PCT/PTO 24 SEP 2004

Substitute for form 1449/PTO
(Revised 04/2003)**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Application Number	Not assigned
				Filing Date	Filed Concurrently Herewith
				First Named Inventor	Moretti
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	049202/281858

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	1	COMMUNAL, C., <i>et al.</i> , "Functional Consequences of Apoptosis in Cardiac Myocytes; Myofibrillar Proteins are Targets for Caspase-3," <i>Circulation</i> , 2001, p. II.162, Vol. 104(17).	Abstract
	2	LAUGWITZ, K-L., <i>et al.</i> , "Blocking Caspase-Activated Apoptosis Improves Contractility in Failing Myocardium," <i>Human Gene Therapy</i> , 2001, pp. 2051-2063, Vol. 12(17).	
	3	MORETTI, A., <i>et al.</i> , "Essential Myosin Light Chain as a Target for Caspase-3 in Failing Myocardium," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, pp. 11860-11865, Vol. 99(18).	
	4	WEIG, H-J., <i>et al.</i> , "Adenoviral Overexpression of P35 Preserves Contractility in Pacing Induced Heart Failure <i>in Vivo</i> ," <i>Circulation</i> , 2000, p. II.165, Vol. 102(18), American Heart Association, USA.	Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.